Fidelity Investments
CATX icon

Fidelity Investments’s Perspective Therapeutics CATX Stock Holding History

Fidelity Investments’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
313,658
+6,603
+2% +$27.9K ﹤0.01% 2780
2025
Q4 		$844K Sell
307,055
-9,703,810
-97% -$27.7M ﹤0.01% 2918
2025
Q3 		$34.3M Sell
10,010,865
-1,091,905
-10% -$3.98M ﹤0.01% 1586
2025
Q2 		$38.2M Buy
11,102,770
+1,052,031
+10% +$2.78M ﹤0.01% 1479
2025
Q1 		$21.4M Buy
10,050,739
+23,438
+0.2% +$70.3K ﹤0.01% 1653
2024
Q4 		$32M Buy
10,027,301
+4,522,479
+82% +$36.9M ﹤0.01% 1560
2024
Q3 		$73.5M Buy
5,504,822
+5,370,392
+3,995% +$71.4M ﹤0.01% 1216
2024
Q2 		$1.34M Buy
+134,430
New +$1.94M ﹤0.01% 2442
2024
Q1 		– Sell
-20
Closed -$171 – 5299
2023
Q4 		$82 Sell
20
-1,780
-99% -$5.01K ﹤0.01% 4961
2023
Q3 		$4.93K Buy
1,800
+1,797
+59,900% +$8.39K ﹤0.01% 4333
2023
Q2 		$18 Buy
+3
New +$18 ﹤0.01% 5197
2023
Q1 		– Sell
-627
Closed -$1.55K – 5301
2022
Q4 		$1.55K Buy
+627
New +$2.07K ﹤0.01% 4567
2021
Q3 		– Sell
-6
Closed – – 4395
2021
Q2 		$0 Buy
+6
New +$53 ﹤0.01% 4288
2019
Q4 		– Sell
-310
Closed -$1K – 3805
2019
Q3 		$1K Buy
+310
New +$1.12K ﹤0.01% 3625

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments's CATX Position: Q1 2026 in Review

Fidelity Investments increased its Perspective Therapeutics (CATX) stake by 2.2% in Q1 2026, buying an estimated $27.9K and bringing the position to 313,658 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2780.

Fidelity Investments first reported a position in CATX in Q3 2019 and has held it in 14 quarters since. The position peaked at $73.5M in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Fidelity Investments held 313,658 shares of Perspective Therapeutics worth $1.31M as of Q1 2026.
  • Fidelity Investments bought 6,603 Perspective Therapeutics shares in Q1 2026, an estimated $27.9K.
  • Perspective Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2780 holding.
  • Fidelity Investments first reported a position in Perspective Therapeutics in Q3 2019 and has held it in 14 quarters since.
  • Fidelity Investments's Perspective Therapeutics position peaked at $73.5M in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.